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D1 Dopamine Receptor Regulation of Microtubule-Associated
Protein-2 Phosphorylation in Developing Cerebral Cortical Neurons
Z.-M. Song,1 A. S. Undie,2 P. O. Koh,1 Y.-Y. Fang,3 L. Zhang,1 S. Dracheva,4 S. C. Sealfon,4 and M. S. Lidow1
Departments of 1Oral and Craniofacial Biological Sciences, 2Pharmaceutical Sciences, and 3Neurology, University of
Maryland, Baltimore, Maryland 21201, and 4Department of Neurology and Dr. Arthur M. Fishberg Research Center for
Neurobiology, Mount Sinai School of Medicine, New York, New York 10029
This study addresses the hypothesis that the previously de-
scribed capacity of D1 dopamine receptors (D1Rs) to regulate
dendritic growth in developing cortical neurons may involve
alterations in the phosphorylation state of microtubule-
associated protein-2 (MAP2). The changes in phosphorylation
of this protein are known to affect its ability to stabilize the
dendritic cytoskeleton. The study involved two systems: pri-
mary cultures of mouse cortical neurons grown in the presence
of the D1R agonists, SKF82958 or A77636, and the cortex of
neonatal transgenic mice overexpressing the D1A subtype of
D1R. In both models, a decrease in dendritic extension corre-
sponded with an elevation in MAP2 phosphorylation. This
phosphorylation occurred on all three amino acid residues
examined in this study: serine, threonine, and tyrosine. In cul-
tured cortical neurons, D1R stimulation-induced increase in
MAP2 phosphorylation was blocked by the protein kinase A
(PKA) inhibitor, H-89, and mimicked by the PKA activator, Sp-
cAMPS. This indicates that D1Rs modulate MAP2 phosphory-
lation through PKA-associated intracellular signaling pathways.
We also observed that the elevations in MAP2 phosphorylation
in neuronal cultures in the presence of D1R agonists (or Sp-
cAMPS) were maintained for a prolonged time (up to at least 96
hr). Moreover, MAP2 phosphorylation underwent a substantial
increase between 24 and 72 hr of exposure to these drugs. Our
findings are consistent with the idea that D1Rs can modulate
growth and maintenance of dendrites in developing cortical
cells by regulating the phosphorylation of MAP2. In addition,
our observations suggest that MAP2 phosphorylation by long-
term activation of D1Rs (and PKA) can be divided into two
phases: the initial 24-hr-long phase of a relatively weak ele-
vation in phosphorylation and the delayed phase of a much
more robust phosphorylation increase taking place during the
next 48 hr.
Key words: D1 dopamine receptor; cerebral cortex; develop-
ment; dendrites; MAP2; protein phosphorylation
Multiple investigations have demonstrated the ability of D1 do-
pamine receptors (D1Rs) to regulate the extension of dendritic
processes in cerebral cortical and other neurons (Lankford et al.,
1987; Rodrigues and Dowling, 1990; Reinoso et al., 1996; Schmidt
et al., 1996; Jones et al., 2000; Zachor et al., 2000). In a great
majority of these studies, D1R activation resulted in reduced
dendritic length. The intracellular mechanisms underlying such
actions of D1Rs, however, have not been examined.
The signal transduction pathways coupled to D1Rs have been
characterized in various cellular systems (for review, see Huff,
1997). In most of these systems, stimulation of D1Rs increases the
intracellular levels of cAMP, leading to activation of cAMP-
dependent protein kinase A (PKA) (Kebabian, 1997). D1Rs may
also interact with other intracellular pathways (Undie and Fried-
man, 1990; Wang et al., 1995) and activate additional protein
kinases, such as protein kinase C (PKC) (Rodrigues and Dowling,
1990). Furthermore, D1R-associated signaling pathways may be
involved in regulating certain serine–threonine and tyrosine
phosphatases (Snyder et al., 1998; Paul et al., 2000). It is likely
that D1R exert its regulatory activity by modulating the phos-
phorylation states of specific cellular proteins through these ki-
nases and phosphatases.
Cytoskeletal proteins have long been recognized to play an
important role in neuronal growth and maturation (Yamada et
al., 1970; Daniels et al., 1975; Keith, 1990; Johnson and Jope,
1992; Shea and Beermann, 1994; Kobayashi and Mundel, 1998).
Among these proteins, microtubule-associated protein-2 (MAP2)
is a major agent responsible for promoting assembly and preser-
vation of dendritic microtubules (for review, see Maccioni and
Cambiazo, 1995; Sanchez et al., 2000), which are the principal
cytoskeletal constituents involved in the growth and maintenance
of dendrites (Yamada et al., 1970; Daniels, 1975; Keith, 1990;
Shea and Beermann, 1994; Kobayashi and Mundel, 1998). This
activity of MAP2 is regulated predominantly via phosphorylation
at multiple sites by PKA, PKC, and other protein kinases (Gold-
enring et al., 1985; Kadowaki et al., 1985; Walaas and Nairn,
1989; Hiraga et al., 1993; Krueger et al., 1997) and via dephos-
phorylation by various serine–threonine and tyrosine phospha-
tases (Yamamoto et al., 1988; Hiraga et al., 1993; Gong et al.,
2000). Changes in the phosphorylation state of MAP2 have been
shown to affect the stability of the dendritic microtubular cy-
toskeleton (Wiche et al., 1991; Maccioni and Cambiazo, 1995;
Sanchez et al., 2000) and, consequently, the number, length, and
branching of dendrites (Diez-Guerra and Avila, 1993, 1995; Au-
desirk et al., 1997).
We hypothesize that at least one of the mechanisms responsi-
ble for the D1R-associated control of dendritic length in cortical
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neurons involves regulation of the phosphorylation state of
MAP2. The present paper describes results of our investigations
in primary cortical neuronal cultures and in D1R-overexpressing
mice that are consistent with this hypothesis. We also show that
D1Rs are capable of long-term regulation of MAP2 phosphory-
lation through PKA-associated pathways. Moreover, these path-
ways were able to affect MAP2 phosphorylation not only on
serine residues, as can be predicted on the basis of studies with
purified PKA and MAP2 (Goldenring et al., 1985; Walaas and
Nairn, 1989), but also on threonine and tyrosine residues. These
findings reveal an additional unanticipated level of complexity in
PKA–MAP2 interactions in live neurons. Furthermore, our ob-
servations suggest that MAP2 phosphorylation resulting from
long-term activation of D1R involves at least two phases: an
initial relatively weak phosphorylation of serine and threonine
residues with no change in tyrosine phosphorylation, and a de-
layed more robust increase in the phosphorylation of all three
residues.
MATERIALS AND METHODS
Primary cultures of cortical neurons. Primary cortical neuronal cultures
were prepared as described previously by Vaccarino et al. (1995) and
Reinoso et al. (1996) with some modifications. Briefly, cerebral cortex of
the frontal lobe, selected as a cortical region rich in D1 dopamine
receptors (Schambra et al., 1994; Gaspar et al., 1995; Lidow, 1995, 1999;
Reinoso et al., 1996), was dissected from CD1 mouse fetuses at embry-
onic day 15 (E15) in ice-cold sterile Ca 2- and Mg 2-free HBSS (Bioflu-
ids). The dissected tissue was triturated with a fire-polished Pasteur
pipette to obtain a suspension of individual cells. The dispersed cells
were plated on 100-mm-diameter Petri dishes (Nalge Nunc Interna-
tional) precoated with poly-L-ornithine and laminin (Sigma, St. Louis,
MO) at a density of 4  10 6 cells per dish in DMEM/F12 medium
supplemented with 10% (v/v) fetal bovine serum, 25 mM HEPES, 2.5 mM
glutamine, 50 IU/ml penicillin, and 50 mg/ml streptomycin (Biofluids).
Petri dishes were placed in a water-jacketed incubator (Forma Scientific)
in 5% CO2/95% air at 37°C. Three hours later, the cultures were washed
with HBSS, and culturing was continued in serum-free glia-conditioned
media (GCM). The GCM used was produced from cultures of the human
astrocytoma cell line U-251 MG. Initial culturing of the latter cells was
performed in Porter flasks (Nalge Nunc International) under conditions
recommended by the cell supplier (American Type Cell Culture). When
cells approached confluence, the flasks were rinsed with HBSS, and the
original medium was replaced with serum-free DMEM/F12 medium,
with the addition of 25 mM HEPES, 2.5 mM L-glutamine, (Biofluids), 1
mM sodium pyruvate, 100 mg/ml transferrin, 5 mg/ml insulin, 20 nM
progesterone, 30 nM sodium selenite, 60 mM putrescine, 50 nM hydrocor-
tisone, 0.5 mg/ml prostaglandin F2a, 10 ng/ml epidermal growth factor,
50 IU/ml penicillin, and 50 mg/ml streptomycin (Sigma). Four days later,
GCM was collected for use in cortical cultures.
Drug exposure. Cultures of cortical cells were allowed to grow for 3 d
before addition of specific drugs (with the exception of one experiment
when drugs were added on the sixth day of culturing). Three days of
culturing before the initiation of experimental manipulations was needed
to allow accumulation of detectable amounts of high molecular weight
neuron-specific MAP2. It also provided for a relatively stable basal level
of phosphorylation of this protein (Diez-Guerra and Avila, 1995). After
these first 3 d, media was replaced once a day in all cultures. For analysis
of the dose–response effects, 10 7-5  10 5 M of the D1R agonists,
SKF82958 or A77636 (RBI), were added for 96 hr. For analysis of the
time course of the effects, 5  10 5 M of the same agonists were added
for periods ranging from 5 min to 96 hr. The D1R specificity of the
agonist actions was tested by the addition of 10 5 M of the D1R antag-
onist, SCH23390 (RBI). The controls consisted of cortical cells cultured
for comparable periods of time either without any dopaminergic drugs or
with 10 5 M SCH23390. To examine whether the observed effects of D1R
stimulation involved PKA-associated intracellular pathways, 3-d-old cul-
tures were coincubated for 2 hr with 5  10 5 M of SKF82958 or A77636
and 10 6 M of the PKA inhibitor, H-89 (Calbiochem). Incubation with
H-89 for longer periods of time was not used because prolonged exposure
to this agent markedly reduced cell viability (see Results). Insight into
the prolonged effects of PKA, however, was gained by examining cell
cultures that were incubated for 2 or 72 hr with 10 6 M of the PKA
activator, Sp-cAMPS (RBI).
Analysis of cell viabilit y in cultures. First, we stained live cultures with
propidium iodine (PI) (Sigma; 3 nM for 5 min), which is known to
selectively visualize apoptotic and necrotic cells (Lizard et al., 1995;
Ertel et al., 1998; Leite et al., 1999; Foglieni et al., 2001). The bright red
PI-stained nuclei were counted under a Leitz Diavert microscope
equipped for detection of fluorescence. For each experimental condition
examined, seven separately generated cultures were evaluated, and for
each culture the counting was performed in 15 randomly selected 0.1
mm 2 fields. Second, live cultures were stained with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma),
which visualizes only living cells the active mitochondria of which are
capable of cleaving the tetrazolium ring in MTT (Mosmann, 1983;
Reinoso et al., 1996). For this purpose, 10 nM MTT and 300 l of 0.04 M
HCl in isopropanol were added to the cultures for 4 hr, after which the
resultant fluorescence at the test wave length of 570 nm and the reference
wave length of 360 nm was measured with a C&L Fluorometer mounted
on a Leitz Diavert microscope. As with PI staining, the measurements
were performed in 15 randomly selected 0.1 mm 2 fields in each of seven
separately generated cultures for every experimental condition exam-
ined. For both staining methods, controls consisted of 7-d-old cultures
grown in glia-unconditioned medium (non-GCM) for 48 hr before
examination.
Immunocytochemistry. For immunocytochemical detection of MAP2
or neuron-specific enolase (NSE), cell cultures were fixed for 5 min in 4%
formaldehyde in PBS, pH. 7.6, and cleared in 0.1% Triton X-100 in PBS
for 30 min. The cultures were then preincubated for 1 hr in 5% normal
goat serum (Sigma). The primary antibodies used were rabbit polyclonal
anti-NSE (1:500 dilution; Biodesign International) and mouse monoclo-
nal anti-MAP2, which label only the neuron-specific high molecular
weight a and b isoforms of MAP2 (1:1000 dilution; Sigma). Cultures were
incubated with the primary antibodies for 18–24 hr at 4°C and then
rinsed in PBS. For NSE detection, the secondary antibodies were Cy3-
conjugated goat anti-rabbit IgGs (Jackson Laboratory). The cultures
were incubated with these antibodies (1:1000 dilution) for 1 hr at room
temperature and then counterstained for 3 min with 300 nM bis-
benzimidazole (BZM; Molecular Probes). For detection of anti-MAP2
primary antibodies, the secondary antibodies were biotinylated goat anti-
mouse IgGs (1:1000 dilution; Jackson Laboratories). The incubation with
these antibodies was also conducted for 1 hr at room temperature. This was
followed by visualization of the labeling with Vectastain Elite ABC kit
(Vector Laboratories) and fast DAB tablets (Sigma). Controls included
omission of the primary antibodies. In the absence of the primary
antibodies, virtually no immunostaining was observed (see Fig. 3F ).
Analysis of the proportion of neurons in cultured cells. This analysis was
performed by comparing the number of neuronal cell bodies identified by
NSE immunolabeling (Schmechel et al., 1980) with the total number of
cell nuclei in the same cultures visualized by BZM counterstaining
(Wang and Lidow, 1997). Images of the stained cultures were captured
and digitized with a SensiCam high-resolution digital video camera
(Cooke) mounted on a Leitz Diavert microscope. Captured images of 15
randomly selected 0.1 mm 2 fields from each of seven separately gener-
ated 3-d-old cultures were used to count the number of green-fluorescent
NSE-immunolabeled cell bodies and blue-fluorescent BZM-stained nu-
clei. Cell counting was performed using IPLab software (Scanalytics).
Morphometric analysis of MAP2-labeled neurites. This analysis was
performed on the basis of the methodology described in Jones et al.
(2000) with modifications by Miguel-Hidalgo et al. (2000). For every
experimental condition examined, images of MAP2 immunolabeling in
15 randomly selected 0.1 mm 2 fields from each of seven separately
generated cultures were digitized with a SensiCam digital video camera
(Cooke) mounted on a Leitz Diavert microscope. For each digitized
image, the percentage of the area occupied by MAP2 staining was
determined using IPLab software (Scanalytics). To verify that the alter-
ations in the area of MAP2 staining in drug-treated cultures were related
to the treatment-induced changes in neurites, the number and average
area of MAP2-expressing soma were also calculated for each field. This
method of analysis was selected, rather than measuring the length of
individual neurites, because outgrowth in the cultures was usually too
extensive to allow consistent tracing of individual processes. Although
plating at lower densities may permit direct measurement of neurite
length, we chose not to use low density plating because such conditions
may subject cultured neurons to extensive stress and alter their responses
to pharmacologic treatments (Jones et al., 2000).
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Animals. Heterozygous male and female transgenic Line-19 mice over-
expressing the D1A subtype of D1R (Dracheva et al., 1999; Dracheva
and Haroutunian, 2001) were bred, and their offspring were genotyped at
birth. The genotyping was performed by quantitative PCR as described
earlier [(Dracheva et al., 1999); this paper also gives levels of D1R in
different cortical regions of transgenic animals]. The sex of the pups was
determined by examining the anogenital distance. The pups were killed
at postnatal day 6, and their brains were collected for analysis. Six-day-
old pups were chosen for this study because by that age all cortical
neurons in this species should reach their adult position and begin to
grow their dendritic trees (Rakic et al., 2000). Procedures for handling of
the animals were approved by the University of Maryland Animal Care
and Use Committee.
Morphological analysis of cortical tissue. In this part of the study, we
used transgenic mice from five litters, with each litter containing two
wild-type, two D1R-overexpressing heterozygous, and two D1R-
overexpressing homozygous males. The mice were anesthetized with 100
mg/kg Nembutal (Abbott Laboratories) and perfused intracardially with
2% paraformaldehyde and 2% glutaraldehyde in 0.2 M phosphate buffer,
pH 7.4. The brains were dissected out, blocked, and postfixed in the same
fixative at 4°C for 7 d. The blocks from the right hemisphere were then
sectioned into 20-m-thick sections on a cryostat. The sections were
stained with cresyl violet and used for the microscopic examination
(under a Zeiss Axioscope microscope) of the general cortical morphol-
ogy in the dorsal part of the anterior cingulate region and in the primary
visual cortex [defined according to Franklin and Paxinos (1997)]. The
thickness of these cortical areas was measured as described by Selemon
et al. (1999). For both areas, we examined at least three sections from
every animal, with the measurement of the cortical thickness being
performed at three random positions along a given area per section. The
tissue blocks from the left hemisphere were washed in distilled water and
placed in 2.5% potassium dichromate (Sigma) in the dark at 4°C for 21 d.
After that, they were washed again and immersed in 0.75% silver nitrate
(Polyscience) in the dark at room temperature for 48 hr. The impreg-
nated blocks were embedded in 12% celloidin (Fisher Scientific) and
sectioned at 250 m on a sliding microtome (Warner Lambert Technol-
ogies). These sections were used for measuring the length of the apical
dendrites of the layer V pyramidal neurons in the same two cortical areas
that were subjected to a general morphological examination on cresyl
violet-stained material. For each cortical area, the measurement was
performed in 10 randomly selected pyramidal neurons per animal, pro-
viding that their overall appearance was similar to that of the general
population of such cells. In addition, the apical dendrites selected for the
analysis had to be fully silver impregnated and running parallel to the
section cut [as recommended by Uylings et al. (1986)]. Glass slides with
Golgi-stained sections were placed on an XYZ motor stage (Ludl Elec-
tronics) fitted on a Zeiss Axioscope microscope equipped with a Sensi-
Cam digital video camera (Cooke). The analysis was performed with
Oncor Imaging Software, which drove the motor stage and automatically
collected a series of images focused through the thickness of the section.
Collected images were used to automatically reconstruct a three-
dimensional (3D) image of the digitized portion of the tissue section. All
visible branches of the apical dendrites were then traced manually. On
the basis of these 3D tracings, we estimated the length of the apical
dendrite from the cell body to its most distal point (Jones et al., 2000) as
well as the combined length of all traced branches of the apical dendrite
(Uylings et al., 1986). We also counted the number of cuts through the
side-branches produced by the microtome knife when the section con-
taining the main body of the dendrite was made. Because all samples
were prepared in a similar manner, no corrections for tissue shrinkage
were introduced. Morphometric analysis was performed by investigators
who were unaware whether the samples were from control or experimen-
tal animals.
Analysis of MAP2 phosphorylation. The phosphorylation of MAP2 on
serine, threonine, and tyrosine residues was examined using a nonradio-
isotopic method as described in Lidow et al. (2001). Culture medium was
aspirated from Petri dishes containing primary neuronal cultures, and 1
ml of ice-cold lysis buffer (20 mM Tris, pH 7.5, 50 mM NaCl, 1% Triton
X-100, 0.5% sodium deoxycholate, 5 mM EDTA, 50 mM sodium fluoride,
40 mM -glycerophosphate, 0.5 mM sodium orthovanadate, 1 mM 4-(2-
aminoethyl)-benzenesulfonyl fluoride, 20 g/ml aprotinin, 2 g/ml leu-
peptin, 2 g/ml pepstatin A; all from Sigma) was added to each dish for
2 min. The lysate buffer with dissociated cells was collected and sonicated
for 30 sec using a Sonic Dismembrator 60 (Fisher Scientific). The
dissected frontal and occipital cortices from 6-d-old mice were homoge-
nized for 3 min in 1 ml of ice-cold lysis buffer using a Cole-Palmer
TriRS63C Homogenizer. The lysates were clarified by centrifugation at
20,000  g for 30 min at 4°C (DuPont RC-S Superspeed Refrigerated
Centrifuge), and the supernatants were processed for MAP2 purification
with an IMMUNOcatcher protein immunoprecipitation kit (CytoSig-
nal). The immunoprecipitating agent (monoclonal MAP2 antibody spe-
cific for the a and b isoforms of MAP2; Sigma) was used at a concen-
tration of 2.5 g/500 g of the total sample protein (determined using
Bradford Protein Assay Kit; Sigma). The resultant immunoprecipitates
were mixed 1:5 with the loading buffer, containing 0.1 M Tris-HCl, pH
6.8, 20% SDS, 50% glycerol, 0.2% Bromophenol blue, and 4.9% DTT
(Sigma), and boiled for 5 min. The proteins in the boiled mixtures (30 l
per well) were resolved by SDS-PAGE for 1.5 hr at 100 V using Ready-
Made 4–15% Gradient SDS Gel in a Ready Gel Cell containing Tris/
Glycin/SDS Running Buffer (Bio-Rad) The resolved proteins were trans-
ferred onto Hybond ECL nitrocellulose membranes (Amersham) for 2 hr
at 100 V using a the same Bio-Rad Gel Cell containing Bio-Rad Tris/
Glycine Buffer with the addition of 0.1% SDS (w/v; Sigma) to ensure a
complete transfer of high molecular weight MAP2 (Wang et al., 1989).
The completeness of transfer was verified by post-staining of gels with
Coomassie blue (Bio-Rad). The membranes were preincubated for 2 hr
with a Membrane Blocking Solution (Zymed Laboratories). To reveal
the phosphorylation states of serine, threonine, and tyrosine residues,
blots were incubated with one of the three antibodies from Zymed: rabbit
anti-phosphoserine (1:250 dilution), anti-phosphothreonine (1:250 dilu-
tion), or anti-phosphotyrosine (1:1000 dilution) at 4°C overnight. Mem-
branes were rinsed five times in TBS containing 0.1% (v/v) Tween 20
(Sigma) and then incubated for 1 hr with horseradish peroxidase (HRP)-
conjugated goat anti-rabbit IgGs (Jackson Laboratories; 1:6500). After
five washes in TBS, bands were visualized using SuperSignal Chemilu-
minescence kit (Pierce) and X-Omat AR Film (Kodak). To detect any
cross-reactivity between antibodies to different phospho-amino acids,
some of the blots were incubated with antibodies that had been prein-
cubated either with 20 ng of the phospho-amino acid to which the antibod-
ies were supposed to bind or with a mixture of the other two phospho-
amino acids (20 ng each) as described in Glenney et al. (1988), Levine et al.
(1989), and Heffeth et al. (1991). We found that preabsorption of all three
antibodies with their specific phospho-amino acids completely abolished
the blot immunolabeling (see Fig. 5). In contrast, preincubation with the
mixture of the other two phospho-amino acids did not affect the immuno-
labeling of blots by any of the three antibodies (Fig. 5).
To detect MAP2 in the same blots, the anti-phospho-amino acid
antibodies were stripped from the membranes by washing in a buffer
containing 62.5 mM Tris-HCl, pH 6.7, 2% SDS, and 100 mM
2-mercaptoethanol at 65°C for 30 min. Membranes were rinsed in PBS,
blocked in Zymed blocking solution for 1 hr, and incubated for 2 hr at
room temperature with monoclonal anti-MAP2 antibodies (1:2000 dilu-
tion; the same clone used for immunocytochemistry and immunoprecipi-
tation). This was followed by 1 hr incubation at room temperature with
HRP-conjugated goat anti-mouse IgGs (Jackson Laboratories; 1:4000
dilution) and visualization by chemiluminescence as described above.
The resultant films were digitized using a Umax UC1260 flat bed scan-
ner, and the densitometric analysis of the bands was performed with
Universal Software (Advanced American Biotechnology).
Samples from all the experimental cell cultures were always processed
together with their controls, and each experiment was repeated seven
times. For each cortical region examined, the samples from wild-type,
heterozygous, and homozygous D1R-overexpressing littermates (two
males of each genotype per litter) were also processed together for all
five litters used in this part of the study. In addition, on all the films used
for comparison of the optical densities of bands generated by experimen-
tal and control samples, these optical densities were within the linear
range of the amount of antigen-generated optical density curve. Such
curves for MAP2, phosphoserine, phosphothreonine, and phosphoty-
rosine were obtained using dot blots of serial dilutions of adult mouse
cerebral cortex followed by immunochemistry with appropriate antibod-
ies as described in Lidow et al. (2001). For every sample, the phosphor-
ylation of MAP2 on each residue was expressed as a ratio of the optical
density of the film images generated by the immunolabeling of MAP2
bands with the appropriate phospho-amino acid-specific antibodies and
the optical density of the film images generated by the immunolabeling
of the same bands with MAP2-specific antibodies. For the tissue cultures,
the ratios of bands generated by the experimental samples were normal-
ized to the ratios generated on the same film by their controls, with the
latter ratios being designated as equal to 1. For the litters of D1R-
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overexpressing mice, the optical density ratios generated by all samples
were normalized to the mean ratio for the samples from the wild-type
littermates, with the latter ratio being designated as equal to 1.
Statistical analysis. The statistical analyses of the effects of different
doses of D1-specific drugs and the effects of PKA-acting substances in
cell cultures were performed with one-way ANOVAs followed by
Tukey’s post hoc comparisons between individual groups. The same
statistical methodology was also used for the evaluation of the data
collected from transgenic animals. The statistical analyses of the time
course of drug effects and the data on cell survival in the cultures were
conducted by two-way ANOVAs with treatment type and duration as
variables. These were followed by Tukey’s post hoc comparisons between
individual groups. The differences were considered significant at p  0.05.
RESULTS
Characterization of the in vitro and in vivo systems
used in this study
Cell cultures
Given that the focus of the present investigation was on cerebral
cortical neurons, it was reasonable to determine the proportion of
neurons in the cortical cell cultures used in this study. The
analysis was performed by comparing the number of neuronal cell
bodies, identified by NSE immunolabeling, and the total number
of cell nuclei, identified by BZM counterstaining, in 3-d-old
cultures (Fig. 1A,B). The analysis was conducted after 3 d of
culturing because this was the time-point at which most drug
treatments were initiated. We found that NSE-immunolabeled
cell bodies constituted 97% of the total number of all cell nuclei
present in the cultures (Fig. 1C). This demonstrates that the
cortical cell cultures used in this study were essentially pure
neuronal cultures.
Decreased neurite density and altered protein phosphorylation
might reflect a general decline in cell viability that is unrelated to
physiologic regulation. To exclude this possibility, we examined
whether the D1R-selective agonists used in the present study
altered viability of cultured cortical cells. Here, two complemen-
tary techniques were applied in live cell cultures: PI labeling,
which accesses cell death, and MTT labeling, which accesses cell
survival and metabolic activity. The counts of PI-stained cells
showed that even the highest used concentration (5  105 M) of
the D1R agonists, SKF82958 and A77636, did not increase the
occurrence of apoptotic–necrotic cells in cultures exposed to
these drugs for up to 96 hr (Fig. 2A,B,D). In both treated and
untreated cultures, the density of PI-stained cells remained at
three to five cells per 0.1 mm2 (Fig. 2D). Quantitative analysis of
the fluorescence resulting from MTT transformation in mito-
chondria of living cells also revealed no statistically significant
differences between drug-free cultures and cultures grown in the
presence of 5  105 M of SKF82958 or A77636 for 24–96 hr
(Fig. 2E). These observations were not associated with poor
staining techniques. The latter was demonstrated by positive
controls, in which 7-d-old cultures were kept for the last 48 hr in
non-GCM. These controls displayed 80 PI-stained cells per 0.1
mm2 as well as a nearly 75% decrease in MTT-associated fluo-
rescence (Fig. 2C–E).
PI and MTT labeling techniques were also used to determine
viability of cell cultures exposed to the other three drugs used in
this study, SCH23390, Sp-cAMPS, and H-98. We found that
neither SCH23390 nor Sp-cAMPS reduced the viability of cells
that were exposed to these drugs after 3 d of culturing at the doses
(105 and 106 M, respectively) and time periods used in the
main body of our research (72 and 96 hr, respectively; data not
shown). However, the concentrations of H-89, which we found to
be effective in our study (106 M), significantly reduced the
viability of cultured cells if applied for 2 hr (for example, after
2 hr exposure to H-89, the MTT-induced fluorescence of cortical
cell cultures decreased by only 3.1  1.4%; 4 hr exposure, how-
ever, reduced this fluorescence by 23.0  3.7%, and 8 hr exposure
produced a 49.8  4.6% reduction in the fluorescence).
The major goal of this study was to evaluate the hypothesis that
the capacity of D1Rs to regulate growth and maintenance of
dendrites may be related to their ability to affect long-term
phosphorylation of MAP2. Therefore, it is important for us to
demonstrate the appropriateness of the selected in vitro models
for this task by demonstrating that stimulation of D1R in our cell
cultures resulted in detectable alterations in dendritic trees. This
was addressed by analyzing the effects of D1R-specific ligands on
the percentage of the area occupied by MAP2-specific immuno-
staining (which visualized neurites and bodies of cultured neu-
rons) within an average 0.1 mm2 fields of cultured cells. Such an
approach was possible because none of the ligand exposure con-
ditions used in the study significantly affected either soma density
or average soma area of cultured cells. Neither were there any
discernable dose- or exposure time-related trends in these two
parameters (Table 1). Hence, any changes in the proportion of
Figure 1. Analysis of the proportion of the neuronal phenotype in cultured cerebral cortical cells. A, Fluorescent immunolabeling of the neuronal
marker, NSE, in paraformaldehyde-fixed cortical cells obtained from the frontal lobe of E15 mouse fetuses and cultured for 3 d. B, The same cells stained
with BZM, which is a fluorescent stain for cell nuclei. Scale bar, 30 m. C, Histograms showing the densities of NSE-immunolabeled neuronal cell bodies
and BZM-stained nuclei in cortical cell cultures. Each bar represents the mean  SEM of seven separately generated cultures. Note that 97% of all
nuclei in these cultures belong to NSE-expressing cell bodies.
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MAP2 immunolabeling in our cultures should reflect changes in
the area occupied by dendritic trees.
The dose dependence of the effects of the D1R agonists,
SKF82958 and A77636, were examined in cultures, which after
3 d of drug-free culturing were grown for 4 additional days in the
presence of increasing concentrations of these agonists. Age-
match cultures grown in the absence of these ligands served as
controls. We found that all drug-exposed cultures displayed a
reduced percentage of the area occupied by MAP2-specific im-
munostaining (Fig. 3A–C; Table 1). The magnitude of this reduc-
tion was concentration dependent, with statistically significant
alterations being detectable beginning at 105 M for both agonists
(Fig. 3A–C; Table 1). At all agonist concentrations examined, the
reduction was blocked by the D1R antagonist, SCH23390 (105
M) (Fig. 3D; Table 1), whereas the antagonist alone did not
produce any significant effects (Fig. 3E; Table 1).
The time course of the D1R agonist effects was examined in
3-d-old cultures exposed for an additional 2–96 hr to 5  105 M
of either SKF82958 or A77636. Compared with age-matched
cultures grown in the absence of these agents, there was a signif-
icant reduction in the proportion of MAP2 staining in cultures
exposed to either agonist at all time periods examined (Table 1).
Interestingly, the percentage of the area occupied by MAP2
immunostaining in cultures exposed to the D1R agonists for 2 hr
was very similar to that in cultures exposed to these agonists for
24 hr (Table 1). However, 48 hr exposure to the D1 agonists
produced a further decrease in the percentage of the area occu-
pied by MAP2 immunostaining (Table 1). This decline was even
more severe in cultures exposed to the agonists for 72 hr (Table
1). Extension of the agonist exposure from 72 to 96 hr did not
result in any further decrease in the area occupied by MAP2-
expressing cells (Table 1). The latter was not because this area
Figure 2. Analysis of cell viability in
cortical cultures. A–C, PI staining of ap-
optotic–necrotic nuclei in live cultures of
cortical cells obtained from the frontal
lobe of E15 mouse fetuses and cultured
for 7 d. A, Cultures grown in the absence
of D1R antagonists; B, cultures that for
the last 96 hr of culturing were exposed to
5  10 5 M of the D1R agonist,
SKF82958. C, Cultures in which cell
death was induced by 48 hr exposure to
glia-unconditioned medium (Non-GCM ).
Scale bar, 25 m. D, Histogram showing
the density of PI-stained apoptotic–ne-
crotic nuclei in cultures of cortical cells
obtained from the frontal lobe of E15
mouse fetuses, which after 3 d of drug-
free culturing were grown for 96 hr either
in the absence of D1R-specific ligands or
in the presence of 5  10 5 M of the D1R
agonists, SKF82958 and A77636. E, His-
togram showing fluorescence resulting
from MTT transformation in mitochon-
dria of live cells in cultures of cortical
cells obtained from the frontal lobe of
E15 mouse fetuses, which after 3 d of
drug-free culturing were grown for an
additional 24–96 hr either in the absence
of D1R-specific ligands or in the presence
of 5  10 5 M of SKF82958 or A77636.
Histograms D and E also include control
cultures in which cell death was induced
by 48 hr exposure to non-GCM. In both
histograms, each column represents the
mean value from seven separately gener-
ated cultures  SEM. Note that D1R
agonist exposure does not induce a sig-
nificant decrease in the viability of cul-
tured cortical cells.
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could no longer be significantly reduced by a further decrease in
neuritic extension, because the area occupied by MAP2-positive
soma was still small enough for additional reductions in the
proportion of MAP2 staining to occur.
This study used PKA modulating agents to test whether D1R
affects MAP2 phosphorylation through the PKA-associated cas-
cade. Therefore, it was of interest to examine the ability of these
drugs to regulate neuritic extension. We found that 2 and 72 hr
applications of 106 M of the PKA activator, Sp-cAMPS, caused
reductions in the area of the culture occupied by MAP2 immu-
nostaining (without reducing either soma density or average soma
area of cultured cells) that were comparable to those induced by
the D1R agonists (Table 1). As noted above, our cell cultures
could not be exposed for 2 hr to the effective concentrations of
the PKA inhibitor, H-89, without significantly reducing their
viability. Nevertheless, during the 2 hr period, 106 M H-89 fully
prevented a decrease in the area of the culture occupied by
MAP2 immunostaining induced by 5  105 M of the two D1R
agonists used in this study (Table 1).
D1R-overexpressing mice
Cortical cell cultures are invaluable for establishing the ability of
D1R to regulate specific biochemical and morphological aspects
of these cells and for investigating the molecular mechanisms of
such regulatory activities. However, the in vitro preparations can
reveal only the potential of D1R to be involved in mediating
similar effects in vivo. To demonstrate that this potential is real-
ized in the brain, we complemented the in vitro assays with studies
in 6-d-old transgenic D1R-overexpressing mice. In preparation
for the analysis of MAP2 phosphorylation in cortical tissues of
the above-mentioned transgenic mice, we examined the overall
morphology and determined the lengths of the apical dendrites of
the layer V pyramidal neurons in the dorsal part of the anterior
cingulate and primary visual cortices of these animals. The ante-
rior cingulate cortex was selected to represent dopamine D1R-
rich cortical areas of the frontal lobe where one would expect to
clearly see the effects of D1R activation (Levitt et al., 1997; Jones
et al., 2000). The primary visual cortex was selected as a control
cortical tissue that is poor in dopaminergic receptors even in
D1R-overexpressing mice (Dracheva et al., 1999) and where one
would expect little manifestation of D1R activity (Levitt et al.,
1997; Jones et al., 2000). The layer V pyramidal neurons were
chosen for analysis as cortical cells most heavily expressing D1R
(Bergson et al., 1995).
Microscopic examinations of cresyl violet-stained sections
through either of the two cortical regions showed that the appear-
ance of cortical lamination and the positioning of pyramidal and
nonpyramidal cells within individual laminas were not different
between homozygous and heterozygous D1R-overexpressing
Table 1. Effects of the exposure to D1R- and PKA-acting drugs on the percentage of the area occupied by MAP2 immunolabeling as well as density


















3 0 None 15.8  1.4 87  11 66.9  5.7
3 2 SKF82958 (5  105 M) 12.1  1.3* 90  13 71.4  6.5
3 2
SKF82958 (5  105 M)
H-89 (106 M) 16.0  1.7 85  14 65.5  5.6
3 2 Sp-cAMPS (10
6 M) 11.8  1.5* 85  15 67.8  5.1
4 0 None 17.2  1.5 91  8 68.3  4.3
4 24 SKF82958 (5  105 M) 12.4  1.6* 86  12 70.0  5.3
5 0 None 18.6  2.5 88  13 66.5  6.8
5 48 SKF82958 (5  105 M) 9.9  1.7** 85  13 73.1  6.6
6 0 None 19.9  2.6 83  11 63.4  5.4
6 72 SKF82958 (5  105 M) 7.6  1.4** 89  14 72.6  6.3
6 72 Sp-cAMPS (10
6 M) 7.9  1.5** 84  13 67.3  4.9
7 0 None 21.8  3.6 84  11 69.9  4.7
7 96 SKF82958 (107 M) 18.3  2.8 95  17 64.7  5.2
7 96 SKF82958 (106 M) 15.6  2.3 87  12 74.1  7.3
7 96 SKF82958 (105 M) 12.0  2.4* 93  14 64.8  6.0
7 96 SKF82958 (5  105 M) 7.7  1.1** 89  14 67.5  5.9
7 96
SKF82958 (5  105 M)
SCH23390 (105 M) 21.5  2.6 82  13 68.9  6.0
7 96 SCH23390 (105 M) 22.9  3.5 87  12 66.7  5.8
The cultures were allowed to grow in drug-free media for 3 d and then some of them were exposed to drugs. The time course of the effects of D1R agonists was examined
by comparing cultures exposed to 5  105 M of these ligands for 2, 24, 48, 72, and 96 hr with the age-matched drug-free cultures (exemplified here by the data produced by
SKF82958). The dose dependence of the effects of D1R agonists was examined in cultures exposed for 96 hr to 0–5  105 M of these ligands (also exemplified here by the
data produced by SKF82958). The D1 receptor specificity of the effects of the agonists was demonstrated by the addition of 105 M of D1R antagonist, SCH23390. The ability
of the PKA stimulator, Sp-cAMPS, to replicate the effects of D1R agonists was examined in cultures exposed to 106 M of this drug for 2 and 72 hr, and the ability of 106
M of the PKA inhibitor, H-89, to block the effects D1R agonists was examined in cultures exposed to a combination of these drugs for only 2 hr (longer exposure to H-89 was
not used because of significant decline in cell viability). Each data point represents a mean of seven separately performed experiments  SEM. The statistically significant
differences between drug-exposed cultures and the age-matched drug-free controls are marked by asterisks (*p  0.05; **p  0.01; Tukey’s post-test). Note D1R
agonist-induced dose- and time-dependent reductions in the percentage of the area occupied by MAP2-immunolabeled cells without any significant changes either in the
density or in the area of the soma of these cells. The addition of a D1R antagonist blocked this reduction, whereas the antagonist alone had no effect. Furthermore, PKA
stimulator replicated the effects of D1R agonists, whereas PKA inhibitor counteracted the effects of these agonists.
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mice and their wild-type littermates (Fig. 4A,B), nor were there
any significant differences between these animal groups in the
thickness of the cerebral cortex (Fig. 4E). These observations
suggest that the alterations in the length of the apical dendrites of
cortical pyramidal cells described in the next paragraph are not a
reflection of some general disorganization of cortical morphology
in D1R-overexpressing animals.
Measurements of the length of the apical dendrites (from the
cell body to their most distal point) of the layer V pyramidal
neurons in the dorsal part of the anterior cingulate cortex showed
Figure 3. Micrographs depicting typical effects of D1R stimulation on neuritic extension in primary cultures of cortical neurons from the frontal lobe
of fetal mouse exemplified by the actions of the D1R antagonist, A77636. Primary cultures of cortical cells obtained from the frontal lobe of E15 mice
were maintained for 3 d in drug-free medium and then grown for an additional 96 hr in the presence of culture medium alone (A), 10 5 M A77636 (B),
5  10 5 M A77636 (C), 5  10 5 M A77636 in combination with 10 5 M SCH23390 (D), and 10 5 M SCH23390 (E). The soma and neurites of neuronal
cells were visualized by the immunolabeling of the heavy molecular weight neuron-specific MAP2. F, Control culture in which immunolabeling was
performed in the absence of the primary antibodies. Scale bar, 60 m. Note the A77636-induced concentration-dependent reductions in the lengths of
MAP2-positive neurites. Although SCH23390 does not show any effects on its own, this D1R antagonist prevents the reductions in neurite extension
induced by A77636.
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them to be significantly shorter in homozygous D1R-
overexpressing mice than in their wild-type littermates (Fig.
4C–F). Homozygous D1R-overexpressing animals also displayed
a significant decrease in the combined length of the traceable
branches of the apical dendrites in the same pyramidal neurons
(Fig. 4C,D,G). Furthermore, the apical dendrites from the latter
animals had fewer cuts produced by a microtome knife during
generation of the tissue sections (Fig. 4G). This indicates that the
decrease in the overall dendritic length observed in homozygous
D1R-overexpressing animals does not result from the extension
of dendritic branches outside of the tissue sections. Moreover, the
decrease in the overall dendritic length in homozygous D1R-
overexpressing animals is most likely underestimated, because
wild-type mice had more cuts through their dendritic branches.
Dendrites of heterozygous animals were of intermediate length.
These same results were obtained both when separate compari-
sons were conducted between members of each of the five litters
examined and when the data for each genotype were pooled
together before analysis.
The comparison of the apical dendrites of the layer V pyrami-
dal neurons from the primary visual cortex of wild-type mice and
their D1R-overexpressing littermates revealed no significant dif-
ferences either in their length from the cell body to the most
distal end or in the combined length of the traceable branches, or
Figure 4. Effects of D1R overexpression on dendritic development in the cortex of 6-d-old transgenic mice. Typical images of cresyl violet-stained
sections through the dorsal part of the anterior cingulate cortex in wild-type mice (A) and their homozygous D1R-overexpressing littermates (B). I–VI,
Cortical layers; W, white matter. Scale bar, 500 m. Examples of the tracing of Golgi silver-impregnated pyramidal layer V neurons from the dorsal part
of the anterior cingulate cortex of the wild-type mice (C) and their homozygous D1R-overexpressing littermates (D). Scale bar, 100 m. E, Histogram
showing the thickness of the dorsal part of the anterior cingulate cortex in wild-type mice (WT ) and their heterozygous (OE1/2) or homozygous (OE2)
D1R-overexpressing littermates. F, Histograms showing the lengths of the apical dendrites measured from the cell body to the most distal point in layer
V pyramidal neurons of the dorsal part of the anterior cingulate (ACd) and primary visual (V1) cortical regions in wild-type mice and their
D1R-overexpressing littermates. G, Histograms showing the combined length of all traceable branches of the same apical dendrites. E, Histograms
showing the number of cuts of the side branches of these apical dendrites that resulted from sectioning of the tissue. In all histograms, each column
represents the mean  SEM of the data pooled from five litters of transgenic animals (n  5), each containing two male representatives of each genotype.
Statistically significant differences between wild-type and D1R-overexpressing littermates are indicated by asterisks (*p  0.05 compared with wild-type
by Tukey’s post hoc test). Note that the layer V pyramidal neurons of the dorsal part of the anterior cingulate cortex display a significant decrease in the
length of their apical dendritic trees (accompanied by a decrease in the proportion of the cuts of dendritic branches produced by tissue sectioning) in
homozygous D1R-overexpressing mice as compared with their wild-type littermates. This takes place in the absence of any noticeable changes either
in cortical cytoarchitecture or in the cortical thickness. In contrast, no corresponding significant changes in dendritic length are present in the primary
visual cortex.
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in the number of branches cut in the preparation of the tissue
sections (Fig. 4F–H).
D1R regulation of MAP2 phosphorylation on serine,
threonine, and tyrosine residues in in vitro and
in vivo models
Blots of neuron-specific high molecular weight MAP2 immuno-
precipitated from either cultured cortical neurons or cortical
tissue homogenates revealed a single band of 280 kDa (Fig. 5).
We believe this to be the b isoform of this protein, which is
present in developing neurons (Binder et al., 1984; Burgoyne and
Cumming, 1984). This MAP2 always displayed phosphorylation
of serine, threonine, and tyrosine residues at all time-points of
culturing that were examined in the present study (Fig. 5).
Studies in in vitro model
We found that 96 hr exposure of cerebral cortical cell cultures to
107-5  105 M of the D1R agonists, SKF82958 and A77636
(after these cultures were grown for 3 d in the absence of
dopaminergic drugs), resulted in a significant increase in MAP2
phosphorylation on all three residues examined in this study. For
all residues, this increase was agonist concentration dependent,
with statistically significant effects being observed at concentra-
tions 105 M and above (Figs. 5, 6). The agonist effects were
prevented by the presence of 105 M of the D1R agonist,
SCH23390 (Figs. 5, 6), whereas this antagonist alone was unable
to affect MAP2 phosphorylation (Fig. 6).
The time course of MAP2 phosphorylation in response to D1R
stimulation was examined in cortical cells that after 3 d of drug-
free culturing were incubated with 5  105 M of SKF82958 or
A77636 for periods from 5 min to 96 hr. Age-matched drug-naive
cultures served as controls. Five minutes of incubation with either
of the D1R agonists resulted in a statistically significant increase
in the phosphorylation of MAP2 on serine and threonine resi-
dues (Fig. 7). Approximately the same levels of elevation in
phosphorylation on these residues were also obtained after 30
min, 2 hr, and 24 hr of agonist exposure (Fig. 7). After 48 hr of
incubation with the D1R agonists, the increase in MAP2 phos-
phorylation on both serine and threonine residues not only failed
to dissipate, but became considerably more prominent than dur-
ing the first 24 hr of agonist exposure (Fig. 7). The increase in
phosphorylation on these two residues was still more robust after
72 hr of agonist exposure and remained at these levels through 96
hr of the exposure (Fig. 7). MAP2 phosphorylation at tyrosine
residues was unchanged from basal levels within the first 24 hr of
incubation with the D1R agonists. Phosphorylation on this resi-
due, however, increased significantly between 48 and 72 hr of the
agonist exposure and then remained steady through 96 hr of the
exposure (Fig. 7). One possible explanation for the increase in
MAP2 phosphorylation seen after 72 hr of agonist exposure is
that it resulted from an altered efficacy of D1R caused by matu-
ration of cultured cells, which by that time were in culture for 6 d.
Such a possibility was investigated in 6-d-old cultures subjected to
5 min applications of SKF82958 or A77636. This produced only a
moderate elevation in MAP2 phosphorylation very similar to that
seen in 3-d-old cultures exposed to the agonists for the same
length of time. This elevation in no way resembled the robust
increase in phosphorylation of MAP2 observed after 72 hr of the
agonist exposure (Fig. 7).
To examine the role of PKA in the D1R agonist induction of
MAP2 phosphorylation, 3-d-old cultures of cerebral cortical cells
were exposed for 2 hr to 5  105 M of either SKF82958 or
A77636 in the presence or absence of 106 M of the PKA
inhibitor, H-89. The application of PKA inhibitor abolished the
increase in MAP2 phosphorylation on serine and threonine res-
idues, which was observed in the presence of SKF82958 or
A77636 alone (Fig. 8). H-89 had no effect on MAP2 phosphory-
lation at tyrosine residues (Fig. 8), which, as indicated above, was
also unaltered by 2 hr exposure to the D1R agonists used in this
Figure 5. Typical Western blots of MAP2 immunoprecipi-
tates from the primary cultures of E15 mouse cerebral corti-
cal neurons, which after 3 d of culturing were maintained for
an additional 96 hr in the presence of 0–5  10 5 M of the D1
dopamine receptor agonist, A77636. Blots of immunoprecipi-
tates from cultures maintained in the presence of a combina-
tion of A77636 and 10 5 M of the D1R antagonist,
SCH23390, are also shown. The blots were initially immuno-
labeled for phosphoserine, phosphothreonine, or phosphoty-
rosine. Control blots were preincubated either with phospho-
amino acids (20 ng) specific for a given antibody (SPAA) or a
mixture of phospho-amino acids nonspecific for these anti-
bodies (NSPAA) (20 ng each). After visualization of the
phospho-amino acids, the labeling was stripped, and the same
blots were immunolabeled again for heavy molecular weight
neuron-specific MAP2. Note an increase in the levels of
phosphorylation on all three residues with an increase in the
concentration of A77636. This effect is blocked by SCH23390.
Also note the lack of cross-reactivity between antibodies to
specific phospho-amino acids.
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study (Figs. 7). The PKA activator, Sp-cAMPS, significantly ele-
vated MAP2 phosphorylation on serine and threonine residues
after 2 hr of exposure and on serine, threonine, and tyrosine
residues after 72 hr of exposure (Fig. 8). Furthermore, the in-
creases in serine or threonine phosphorylation were much greater
after 72 hr than after 2 hr of exposure to Sp-cAMPS (Fig. 8).
Therefore, the actions of Sp-cAMPS closely mimicked those of
D1R agonists.
Figure 6. Histograms showing D1R agonist concentration dependence
of MAP2 phosphorylation on serine, threonine, and tyrosine residues.
The data are presented as the ratios between MAP2 phosphorylation on
specific residues in cultures of E15 mouse cortical neurons, which after 3 d
of drug-free culturing were incubated for an additional 96 hr with 10 7–
5  10 5 M of the D1R agonist, SKF82958, and MAP2 phosphorylation
on the same residues in cultures maintained for the comparable periods of
time without the addition of D1R ligands. In addition, the histograms
show the ratios between MAP2 phosphorylation in cultures incubated
with either a combination of SKF82958 and 10 5 M of the D1R antago-
nist, SCH23390, or with 10 5 M of this antagonist alone and MAP2
phosphorylation in corresponding drug-free cultures. All of these ratios
were obtained using seven drug-exposed and seven drug-naive cultures
maintained for the same period of time. Error bars are SEMs. The ratios
representing statistically significant differences between experimental and
corresponding control cultures are marked by asterisks (*p  0.05; **p 
0.01; Tukey’s post-test). Note that increasing concentrations of the D1R
agonist induce corresponding increases in the levels of MAP2 phosphor-
ylation on all three residues. These effects are blocked by the D1R
antagonist.
Figure 7. Histograms showing the time course of MAP2 phosphoryla-
tion on serine, threonine, and tyrosine residues in cultures of E15 mouse
cortical neurons that after 3 d of culturing were exposed from 5 min to 96
hr to 5  10 5 M of the D1R agonists, SKF82958 and A77636. MAP2
phosphorylation in cultures that on the sixth day were exposed to
SKF82958 for 5 min are also presented. The MAP2 phosphorylation in all
of these cultures was expressed as a ratio to that in cultures maintained for
the same period of time without the addition of D1R ligands. All of the
ratios were obtained using seven drug-exposed and seven drug-naive
cultures maintained for the same period of time. Error bars are SEMs.
The ratios representing statistically significant differences between exper-
imental and corresponding control cultures are marked by asterisks (*p 
0.05; **p  0.01; Tukey’s post-test). Note that 5 min to 24 hr of exposure
to D1R agonists results in a moderate increase in MAP2 phosphorylation
on serine and threonine residues. Also, note further enhancements in
MAP2 phosphorylation on serine and threonine residues as well as
significant increases in phosphorylation on tyrosine residues after 48 hr of
agonist exposure. Even larger increases in phosphorylation on all three
residues are detectable after 72 and 96 hr of the exposure. Finally, note
the similarity in the magnitudes of increase in MAP2 phosphorylation
produced by 5 min exposure to D1R agonists in 3- and 6-d-old cultures.
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Studies in the in vivo model
Analysis of MAP2 immunoprecipitates obtained from cortical
preparations of the frontal lobe revealed significant increases in
phosphorylation of all three amino acid residues in homozygous
D1R-overexpressing mice as compared with their wild-type lit-
termates (Fig. 9A). MAP2 phosphorylation in heterozygous ani-
mals had intermediate values (Fig. 9A). Similar conclusions were
reached when separate comparisons were conducted between
members of each of the five litters examined and when the data
for each genotype were pooled together before analysis. In con-
trast, MAP2 immunoprecipitates from the control dopamine
receptor-poor occipital cortex showed no statistically significant
differences in phosphorylation between wild-type animals and
their D1R-overexpressing littermates (Fig. 9B).
DISCUSSION
The central finding of this study is that D1Rs are capable of
regulating the phosphorylation of MAP2 on all three phosphor-
ylatable residues examined: serine, threonine, and tyrosine.
Moreover, in cultures of both mouse cortical neurons and trans-
genic D1R-overexpressing neonatal mice, decreases in the exten-
sion of dendritic processes corresponded with increases in the
levels of MAP2 phosphorylation. In particular, alterations in
MAP2 phosphorylation and in neurite development in cultured
cortical neurons displayed matching dose-dependence for the two
D1R-specific agonists used in our investigations, with both effects
reaching statistically significant levels in cultures exposed to the
agonists at concentrations of 105 M or greater. Furthermore,
both the decreases in neurite extension and the increases in
MAP2 phosphorylation induced by D1R agonists were inhibited
by the addition of the D1R antagonist, SCH23390. There was also
a remarkable similarity between the time courses of changes in
MAP2 phosphorylation and in neurite extension in cultures
grown in the presence of D1R agonists. For both parameters, the
initial, rather modest changes were maintained for the first 24 hr.
These changes, however, become more pronounced after 48 hr of
agonist exposure and increased even further during the subse-
quent 72 hr of exposure. Longer durations of agonist exposure
(up to 96 hr), however, produced no additional augmentations
either in MAP2 phosphorylation or neurite extension. In addi-
tion, the application of a drug that prevented the D1R agonist-
induced increase in MAP2 phosphorylation also abolished the
reduction in neuritic extension caused by these agonists, whereas
the application of a drug that mirrored D1R agonists in increas-
ing MAP2 phosphorylation also resulted in a decrease in neuritic
extension. Finally, the presence of both reduced dendritic length
and increased MAP2 phosphorylation was seen in the cortex of
the frontal lobe of D1R-overexpressing mice, which is the region
where the number of D1Rs should be sufficiently high to allow
them to influence neuronal development (these alterations were
observed not only in 6-d-old mice described in this study, but also
in adult 50-d-old animals; M. S. Lidow, unpublished observa-
tions). In contrast, no significant alterations either in dendritic
length or in MAP2 phosphorylation were detected in the occipital
cortex of the same animals, which is the region where the number
of D1Rs should be too low to have a developmental impact. The
latter observation, along with the apparent absence of any cyto-
architectonic abnormalities in the cortex of the transgenic mice,
Figure 8. Histograms providing the comparison of the levels of MAP2 phosphorylation on serine, threonine, and tyrosine residues between cultures
of E15 mouse cortical neurons, which after 3 d of culturing were exposed for an additional 2 or 72 hr to 5  10 5 M of the D1R agonist, A77636, and
cultures exposed for the same durations either to 10 6 M of the PKA activator, Sp-cAMPS, or to 5  10
5 M A77636 combined with 10 6 M of the PKA
inhibitor, H-89. The latter drug combination was applied only for 2 hr, because longer exposure to H-89 led to a significant decline in cell viability. MAP2
phosphorylation in all of these cultures was expressed as a ratio to that in control cultures maintained for the same period of time without any drugs being
added to the culture medium. All of the ratios were obtained using seven drug-exposed and seven drug-naive cultures maintained for the same period
of time. Error bars are SEMs. The ratios representing statistically significant differences between experimental and corresponding control cultures are
marked by asterisks (*p  0.05; **p  0.01; Tukey’s post-test). Note the similarity in the effects of the D1R agonist and the PKA activator. Also note
that the effects of the D1R agonist are blocked by the PKA inhibitor.
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indicates that the alterations in dendritic length and MAP2
phosphorylation seen in the cortex of the frontal lobe of D1R-
overexpressing animals were specific consequences of an increase
in the levels of D1R in this cortical region. Taken together, our in
vitro and in vivo findings support the idea that stimulation of D1R
downregulates dendritic extension in developing cerebral cortical
neurons, at least in part, by increasing the phosphorylation of
MAP2 and thus suppressing the ability of this protein to promote
the assembly and stability of the dendritic microtubular cytoskel-
eton (for review, see Maccioni and Cambiazo, 1995; Sanchez et
al., 2000).
The present study suggests that the ability of D1Rs to increase
phosphorylation of MAP2 most likely involves activation of
PKA-associated intracellular signaling pathways because a PKA
activator was able to replicate and a PKA inhibitor was able to
block these effects of D1R agonists. Previous analyses of phos-
phorylation in purified MAP2 preparations suggested that PKA
directly phosphorylates this protein only on serine residues
(Goldenring et al., 1985; Walaas and Nairn, 1989). In our study,
however, the increases in MAP2 phosphorylation were detected
not only on serine but also on threonine and tyrosine residues of
this protein (Tsuyama et al., 1987). We speculate that such an
effect is possible because in intact cortical neurons PKA may be
involved in indirect regulation of MAP2 phosphorylation on the
latter two residues. For example, it has been shown that stimula-
tion of neuronal D1R leads to a PKA-mediated activation of Mr
32 kDa phosphoprotein, DARPP-32, which acts as an inhibitor of
protein phosphatase-1 (PP1) (Snyder et al., 1998). The latter
phosphatase is involved in dephosphorylation of MAP2 on serine
and threonine residues (Yamamoto et al., 1988; Sanchez et al.,
1996). Therefore, deactivation of PP1 should lead to a net in-
crease in MAP2 phosphorylation on these residues. PKA may
also be involved in deactivation of tyrosine phosphatases (Ito et
al., 1997; Paul et al., 2000), which would result in an increased
level of tyrosine phosphorylation on their respective substrate
proteins, including MAP2 (Hiraga et al., 1993). In addition, PKA
is known to activate intracellular cascades that are associated
with other kinases (Kim et al., 1997; Vossler et al., 1997; Blanco-
Aparicio et al., 1999; Ambrosini et al., 2000) capable of phos-
phorylating MAP2 on multiple residues (for review, see Sanchez
et al., 2000).
An important discovery of this study is that the increase in
MAP2 phosphorylation was detectable as early as 5 min after
D1R agonists were added and was maintained for as long as these
agonists were present in the culture medium (up to 4 d). In
addition, an increase in MAP2 phosphorylation was observed in
the cortex of neonatal mice genetically manipulated to perma-
nently overexpress the D1A subtype of D1R. These observations
suggest that the changes in MAP2 phosphorylation are involved
not only in short-term modulation but also in long-term control of
the activity of this protein by D1Rs. Chronic alterations in MAP2
phosphorylation have previously been described in the cerebral
cortex after prolonged administration of aluminum, antidepres-
sant, and antipsychotic medications (Johnson and Jope, 1988;
Miyamoto et al., 1997; Lidow et al., 2001). Thus, it is possible that
long-term regulation of MAP2 phosphorylation is a common
neuroregulatory mechanism used by diverse endogenous, thera-
peutic, and toxic agents.
Figure 9. Histograms showing the effects of D1 dopa-
mine receptor overexpression in the cortex of 6-d-old
transgenic mice on the levels of MAP2 phosphorylation
on serine, threonine, and tyrosine residues. A, Cortex of
the frontal lobe; B, cortex of the occipital lobe. WT,
Wild-type animals; OE1/2, their heterozygous D1R-
overexpressing littermates; OE2, their homozygous D1R-
overexpressing littermates. In both histograms, each col-
umn represents the mean value of the data pulled from
five litters of transgenic animals (n  5), each containing
two male representatives of each genotype. The error
bars are SEMs. The statistically significant differences
between wild-type and D1R-overexpressing littermates
are marked by asterisks ( p  0.05; Tukey’s post-test).
Note a significant increase in MAP2 phosphorylation on
all three residues in the cortex of the frontal lobe of
D1R-overexpressing homozygous mice. No such signifi-
cant increase in MAP2 phosphorylation is observed in the
occipital cortex of same animals.
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The present data further show that persistent D1R stimulation
increases MAP2 phosphorylation in two phases. The first phase,
taking place during the first 24 hr of the stimulation, consists of a
moderate increase in phosphorylation of this protein on serine
and threonine residues, with no statistically significant change in
tyrosine phosphorylation. The second phase consists of an addi-
tional robust increase in MAP2 phosphorylation that is evident
on all three residues. We detected this delayed elevation in
MAP2 phosphorylation after 48 hr of exposure to the D1R
agonists used in this study and found it to be particularly notable
in cultures maintained in the presence of these agonists for 72 hr
or longer. The second phase of the augmentation in MAP2
phosphorylation is likely induced by the prolonged D1R stimu-
lation rather than being related to maturation-associated changes
in cell physiology. This is demonstrated by the observation that a
5 min exposure of cultured cells to D1R agonists produced
elevations in MAP2 phosphorylation that were similar in magni-
tude in both 3- and 6-d-old cultures. Furthermore, the delayed
increase in MAP2 phosphorylation (as well as the accompanying
decrease in the extension of neurites) could not be easily ex-
plained by a general toxicity of our D1R-specific ligands. Such
toxicity should have lead to a significant decline in cell viability,
yet it remained unchanged in our cell cultures even at the highest
D1R ligand concentrations and the longest exposures used in the
present studies. In addition, there were no ligand exposure-
associated changes in the size or density of neuronal soma in our
cultures. Finally, that the delayed increase in MAP2 phosphory-
lation is a normal regulatory response to prolonged stimulation of
D1R is suggested by the fact that the alterations in phosphoryla-
tion on tyrosine residues, which are a part of this delayed in-
crease, are also seen in D1R-overexpressing mice.
The reasons for the existence of these two phases in the
induction of MAP2 phosphorylation by D1R stimulation are
presently unknown. We speculate that although the first phase
likely results directly from increased activation of cAMP–PKA-
associated intracellular cascades, the second phase may reflect
possible recruitment of some additional mechanisms that ulti-
mately produce an enhancement of protein phosphorylation.
Such additional mechanisms could include upregulation of PKA
expression and translocation of PKA from the cytosolic compart-
ments to the cytoskeletal or membrane compartments. Both of
these effects have been observed after prolonged treatment with
antidepressants (Perez et al., 1991; Racagni et al., 1992; Mori et
al., 1998a,b). Long-term changes in the expression and/or loca-
tion of other protein kinases and phosphatases also cannot be
excluded. We are presently evaluating these possibilities.
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